Moreno-Martinez, E, de la Serna-Torroba, J, Escudero-Vilaplana, V, Hernandez-Rivas, JA, Sanchez-Cuervos, M, Sanchez-Hernandez, R. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain. Farmacia Hospitalaria. 2022; 46(3)DOI:10.7399/fh.11829. PMID:36183205. IF:(Q/D).

Fernandez-Arevalo, A, Ballart, C, Munoz-Basagoiti, J, Basarte, L, Lobato, G, Arnau, A, Abras, A, Tebar, S, Llovet, T, Lami, P, Pratlong, F, Alsina, M, Roe, E, Puig, L, Munoz, C, Gallego, M. Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers. Transboundary and Emerging Diseases. 2022; 69(3)DOI:10.1111/tbed.14107. PMID:33864706. IF:4.300(Q1/1D).

Garcia-Melendo, C, Morales-Munera, CE, Dalmau, J, Cubiro, X, Lopez-Sanchez, C, Mozos, A, Yelamos, O. Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma. Dermatologic Therapy. 2022; 35(5)DOI:10.1111/dth.15388. PMID:35174945. IF:3.600(Q1/3D).

Sanz, C, Nomdedeu, M, Pereira, A, Sauleda, S, Alonso, R, Bes, M, Brillembourg, H, Garcia-Vidal, C, Millan, A, Martinez-Llonch, N, Piron, M, Puerta-Alcalde, P, Puig, L, Rico, V, Soriano, A. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. TRANSFUSION. 2022; 62(5)DOI:10.1111/trf.16863. PMID:35338710. IF:2.900(Q3/7D).